
KKR closes USD 4bn healthcare fund
Global private equity firm KKR has closed a USD 4bn fund for healthcare investments in Europe and North America.
Health Care Strategic Growth Fund II (HCSG II) is the successor to HCSG I, which closed in November 2017 on USD 1.45bn.
KKR stated that the fund will focus on the biopharmaceutical, medical devices, healthcare services, life sciences tools and diagnostics, and healthcare information technology sub-sectors.
The PE firm added that the fund is backed by new and existing LPs, including public pension plans, sovereign wealth funds, insurance companies, financial institutions, endowments, private wealth and fintech platforms, family offices, and high-net-worth individual investors.
KKR will invest USD 500m of its own capital into the fund. The firm has invested USD 18bn in healthcare since 2004.
In 2021, KKR acquired New Zealand-based animal-health pharma platform Argenta and US medical devices maker Cordis. It also took a minority stake in Denmark-based Nordic Bioscience and invested in US-based Sapphiros.
Latest News
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Multi-family office has seen strong appetite, with investor base growing since 2016 to more than 90 family offices, Meiping Yap told Unquote
Permira to take Ergomed private for GBP 703m
Sponsor deploys Permira VIII to ride new wave of take-privates; Blackstone commits GBP 200m in financing for UK-based CRO
Partners Group to release IMs for Civica sale in mid-September
Sponsor acquired the public software group in July 2017 via the same-year vintage Partners Group Global Value 2017
Change of mind: Sponsors take to de-listing their own assets
EQT and Cinven seen as bellweather for funds to reassess options for listed assets trading underwater